Index RUT
P/E -
EPS (ttm) -0.75
Insider Own 14.99%
Shs Outstand 35.17M
Perf Week 4.50%
Market Cap 369.51M
Forward P/E 17.61
EPS next Y 0.59
Insider Trans 4.16%
Shs Float 30.06M
Perf Month -20.23%
Income -24.41M
PEG -
EPS next Q -0.20
Inst Own 65.18%
Short Float 19.70%
Perf Quarter 9.65%
Sales 130.19M
P/S 2.84
EPS this Y 57.00%
Inst Trans -4.54%
Short Ratio 12.51
Perf Half Y -27.10%
Book/sh 2.00
P/B 5.22
EPS next Y 283.98%
ROA -10.41%
Short Interest 5.92M
Perf Year -59.20%
Cash/sh 2.34
P/C 4.46
EPS next 5Y 15.00%
ROE -49.84%
52W Range 7.60 - 28.25
Perf YTD -6.70%
Dividend Est. -
P/FCF 155.26
EPS past 5Y -
ROI -9.39%
52W High -63.01%
Beta 0.72
Dividend TTM -
Quick Ratio 2.60
Sales past 5Y 27.34%
Gross Margin 69.55%
52W Low 37.50%
ATR (14) 0.63
Dividend Ex-Date -
Current Ratio 2.82
EPS Y/Y TTM -44.20%
Oper. Margin 0.62%
RSI (14) 40.44
Volatility 5.49% 5.50%
Employees 315
Debt/Eq 2.71
Sales Y/Y TTM 46.95%
Profit Margin -18.75%
Recom 1.00
Target Price 25.65
Option/Short Yes / Yes
LT Debt/Eq 2.70
EPS Q/Q -822.91%
Payout -
Rel Volume 0.28
Prev Close 10.43
Sales Surprise -3.97%
EPS Surprise -500.46%
Sales Q/Q 78.83%
Earnings May 13 AMC
Avg Volume 473.32K
Price 10.45
SMA20 -10.14%
SMA50 -8.67%
SMA200 -19.15%
Trades
Volume 61,931
Change 0.19%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-11-24 Initiated
Craig Hallum
Buy
$24
Sep-08-22 Resumed
B. Riley Securities
Buy
$17
Oct-14-21 Resumed
B. Riley Securities
Buy
$16
Sep-24-21 Initiated
Aegis Capital
Buy
$15
Jul-02-21 Initiated
Ladenburg Thalmann
Buy
$14.25
Apr-25-24 07:00AM
Apr-02-24 08:16AM
Mar-21-24 09:55AM
Mar-19-24 09:52PM
06:51PM
05:45PM
Loading…
05:45PM
Mar-13-24 06:35AM
Mar-05-24 07:00AM
Mar-04-24 08:28PM
Feb-21-24 06:47AM
Feb-15-24 04:01PM
Jan-29-24 07:00AM
Jan-11-24 07:00AM
Jan-03-24 07:15AM
07:00AM
01:08PM
Loading…
Dec-24-23 01:08PM
Nov-29-23 07:00AM
Nov-20-23 07:00AM
Nov-14-23 12:56PM
Nov-13-23 05:07PM
04:01PM
Oct-30-23 08:00AM
Oct-24-23 07:00AM
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-21-23 01:03PM
Aug-11-23 01:05PM
Aug-10-23 09:54AM
(Thomson Reuters StreetEvents) -15.45%
Aug-09-23 04:14PM
(Associated Press Finance)
04:01PM
07:00AM
Loading…
Jul-31-23 07:00AM
Jul-28-23 02:56PM
Jul-26-23 03:42PM
(American City Business Journals)
09:00AM
Jul-20-23 10:29AM
Jul-19-23 12:17PM
07:00AM
Jul-18-23 05:00PM
04:05PM
04:04PM
04:01PM
Jul-05-23 06:15PM
Jun-29-23 06:15PM
Jun-23-23 06:15PM
Jun-16-23 06:00PM
May-17-23 08:00AM
May-16-23 11:57AM
May-15-23 11:21AM
May-12-23 01:48PM
06:26AM
(Thomson Reuters StreetEvents)
May-11-23 05:15PM
04:29PM
04:01PM
May-08-23 12:07PM
May-04-23 08:00AM
04:59AM
May-03-23 06:44AM
May-02-23 04:42PM
09:40AM
07:00AM
May-01-23 08:50AM
Apr-28-23 06:00PM
05:00AM
Apr-27-23 08:05AM
08:00AM
Apr-24-23 08:43AM
07:09AM
Apr-20-23 08:31AM
Apr-19-23 06:15PM
08:31AM
Apr-18-23 06:24AM
Apr-14-23 08:50AM
Apr-13-23 06:15PM
Apr-12-23 09:40AM
Apr-09-23 04:04PM
(The Wall Street Journal)
Apr-05-23 09:34AM
Apr-04-23 05:37AM
Apr-03-23 06:53AM
Mar-29-23 08:50AM
Mar-28-23 02:59PM
07:00AM
Mar-27-23 08:51AM
Mar-24-23 05:42AM
(Thomson Reuters StreetEvents) +6.78%
Mar-23-23 04:06PM
Mar-13-23 07:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-16-23 06:42AM
Feb-15-23 07:00AM
Feb-03-23 08:50AM
Feb-02-23 06:30AM
Jan-23-23 07:00AM
Jan-21-23 07:33AM
Jan-18-23 08:50AM
Jan-05-23 07:00AM
Dec-25-22 07:24AM
Dec-21-22 09:21AM
Dec-16-22 07:00AM
Dec-14-22 03:24PM
(American City Business Journals) +15.05%
09:41AM
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Opaleye Management Inc. 10% Owner Apr 25 '24 Buy 9.97 20,000 199,400 3,815,000 Apr 25 05:19 PM Opaleye Management Inc. 10% Owner Apr 24 '24 Buy 10.15 8,285 84,093 3,795,000 Apr 24 04:40 PM Opaleye Management Inc. 10% Owner Apr 23 '24 Buy 10.29 11,715 120,547 3,786,715 Apr 24 04:40 PM Opaleye Management Inc. 10% Owner Apr 19 '24 Buy 10.56 29,400 310,390 3,775,000 Apr 19 06:24 PM Opaleye Management Inc. 10% Owner Mar 28 '24 Buy 12.82 50,000 641,000 3,745,600 Mar 28 06:07 PM BAUM MARK L CHIEF EXECUTIVE OFFICER Mar 22 '24 Buy 11.59 9,000 104,310 2,137,525 Mar 25 07:00 AM Opaleye Management Inc. 10% Owner Mar 20 '24 Buy 9.65 50,600 488,290 3,695,600 Mar 22 11:52 AM SAHAREK JOHN P. CEO of ImprimisRx Mar 01 '24 Option Exercise 8.75 5,000 43,750 254,803 Mar 06 06:06 AM BAUM MARK L CHIEF EXECUTIVE OFFICER Feb 20 '24 Option Exercise 10.67 150,000 1,600,500 2,188,361 Feb 21 07:29 PM BOLL ANDREW R. CHIEF FINANCIAL OFFICER Feb 20 '24 Option Exercise 10.67 45,000 480,150 586,569 Feb 21 07:29 PM SAHAREK JOHN P. CEO of ImprimisRx Feb 20 '24 Option Exercise 10.67 30,000 320,100 262,419 Feb 21 07:30 PM BAUM MARK L CHIEF EXECUTIVE OFFICER Feb 07 '24 Option Exercise 7.71 15,400 118,734 2,038,361 Feb 08 07:30 AM BOLL ANDREW R. CHIEF FINANCIAL OFFICER Feb 07 '24 Option Exercise 7.71 7,400 57,054 541,569 Feb 08 07:30 AM BAUM MARK L Chief Executive Officer Nov 16 '23 Buy 8.11 7,500 60,825 2,022,961 Nov 16 04:45 PM Opaleye Management Inc. 10% Owner Nov 15 '23 Buy 8.03 25,000 200,735 3,645,000 Nov 16 04:05 PM Opaleye Management Inc. 10% Owner Sep 20 '23 Buy 14.49 5,983 86,710 3,620,000 Sep 20 06:39 PM Opaleye Management Inc. 10% Owner Sep 19 '23 Buy 14.65 14,017 205,366 3,614,017 Sep 20 06:39 PM Makary Martin A. Director Aug 14 '23 Buy 16.92 20,000 338,400 45,000 Aug 15 07:30 AM BAUM MARK L Chief Executive Officer Aug 14 '23 Buy 17.05 5,800 98,890 2,015,461 Aug 15 07:30 AM
Index -
P/E -
EPS (ttm) -5.20
Insider Own 7.89%
Shs Outstand 2.21M
Perf Week 2.79%
Market Cap 4.20M
Forward P/E -
EPS next Y -3.69
Insider Trans 0.00%
Shs Float 2.10M
Perf Month -58.09%
Income -3.59M
PEG -
EPS next Q -1.19
Inst Own 11.02%
Short Float 1.16%
Perf Quarter -52.82%
Sales 12.04M
P/S 0.35
EPS this Y -115.76%
Inst Trans -
Short Ratio 0.10
Perf Half Y -48.20%
Book/sh -0.37
P/B -
EPS next Y 22.33%
ROA -24.26%
Short Interest 0.02M
Perf Year -86.74%
Cash/sh 3.75
P/C 0.49
EPS next 5Y -
ROE -
52W Range 1.59 - 16.00
Perf YTD -47.46%
Dividend Est. -
P/FCF 1.14
EPS past 5Y 61.51%
ROI -
52W High -88.50%
Beta 1.31
Dividend TTM -
Quick Ratio 0.89
Sales past 5Y -40.00%
Gross Margin 99.88%
52W Low 15.72%
ATR (14) 0.63
Dividend Ex-Date -
Current Ratio 0.89
EPS Y/Y TTM 81.52%
Oper. Margin -57.27%
RSI (14) 35.46
Volatility 12.46% 25.33%
Employees 17
Debt/Eq -
Sales Y/Y TTM -100.00%
Profit Margin -29.79%
Recom 1.67
Target Price 37.50
Option/Short No / Yes
LT Debt/Eq -
EPS Q/Q 103.48%
Payout -
Rel Volume 0.41
Prev Close 1.71
Sales Surprise 103.00%
EPS Surprise 112.50%
Sales Q/Q -
Earnings Mar 05 AMC
Avg Volume 246.65K
Price 1.84
SMA20 -26.19%
SMA50 -61.32%
SMA200 -57.31%
Trades
Volume 46,823
Change 7.60%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-16-21 Upgrade
BTIG Research
Neutral → Buy
$14
Feb-10-21 Initiated
Maxim Group
Buy
$24
Dec-23-19 Reiterated
H.C. Wainwright
Buy
$15 → $18
Mar-01-19 Reiterated
Needham
Buy
$7
Jun-13-17 Reiterated
Stifel
Buy
$14 → $6
Dec-21-16 Initiated
Jefferies
Buy
$10
Feb-01-16 Resumed
Oppenheimer
Outperform
Jul-29-15 Initiated
ROTH Capital
Buy
$18
Mar-02-15 Reiterated
Stifel
Buy
$16 → $20
Mar-02-15 Reiterated
Oppenheimer
Outperform
$22 → $26
Feb-24-15 Initiated
Stifel
Buy
$16
Feb-24-15 Initiated
Oppenheimer
Outperform
$22
Show Previous Ratings
Apr-10-24 06:30AM
Apr-08-24 09:10AM
Apr-03-24 08:00AM
Mar-07-24 10:03AM
Mar-05-24 04:29PM
(Associated Press Finance)
04:02PM
Loading…
04:02PM
Feb-28-24 04:02PM
Dec-20-23 08:00AM
Nov-21-23 07:55AM
07:32AM
Nov-20-23 08:00AM
Nov-13-23 09:29AM
Nov-12-23 08:47AM
Nov-10-23 07:45AM
Nov-09-23 04:58PM
(Associated Press Finance)
04:02PM
Loading…
04:02PM
Oct-31-23 04:02PM
Sep-18-23 08:00AM
Sep-05-23 04:02PM
Aug-25-23 07:20AM
Aug-15-23 08:43AM
(Thomson Reuters StreetEvents) -6.95%
Aug-14-23 07:00PM
(Associated Press Finance) -9.66%
04:02PM
Aug-02-23 04:05PM
Jul-11-23 08:00AM
Jun-20-23 08:00AM
Jun-16-23 08:00AM
Jun-15-23 08:00AM
Jun-02-23 08:00AM
May-30-23 08:00AM
11:24AM
Loading…
May-11-23 11:24AM
(Thomson Reuters StreetEvents) -6.14%
May-10-23 04:38PM
04:02PM
May-03-23 04:02PM
Apr-25-23 07:41AM
Apr-06-23 08:30AM
Mar-14-23 12:00PM
Mar-10-23 02:26AM
Mar-09-23 05:49AM
(Thomson Reuters StreetEvents)
Mar-08-23 04:02PM
Feb-28-23 04:02PM
Jan-20-23 06:55AM
Jan-10-23 08:30AM
Dec-27-22 08:00AM
Dec-14-22 11:29AM
08:00AM
Nov-21-22 08:00AM
Nov-14-22 04:02PM
Oct-31-22 08:00AM
Oct-06-22 08:30AM
08:00AM
Sep-14-22 08:00AM
Sep-07-22 08:00AM
Sep-06-22 08:00AM
Aug-29-22 08:00PM
11:45AM
08:00AM
Aug-10-22 04:02PM
08:00AM
Aug-08-22 08:00AM
Jul-27-22 08:05AM
Jul-26-22 08:05AM
Jun-02-22 08:05AM
May-16-22 08:05AM
May-11-22 04:02PM
May-04-22 08:05AM
Apr-19-22 08:05AM
Apr-08-22 05:02PM
Mar-23-22 08:05AM
Mar-15-22 04:02PM
Mar-11-22 08:05AM
Mar-10-22 08:05AM
Mar-04-22 08:05AM
Feb-02-22 08:05AM
Jan-05-22 08:05AM
Dec-27-21 08:00AM
Nov-29-21 08:05AM
Nov-11-21 08:05AM
Nov-03-21 04:02PM
Oct-27-21 08:05AM
Oct-13-21 08:00AM
Oct-11-21 01:27PM
08:00AM
Sep-13-21 08:05AM
Sep-07-21 08:05AM
07:29AM
Sep-02-21 08:05AM
Aug-11-21 04:02PM
Aug-09-21 08:05AM
Aug-03-21 08:05AM
Jul-28-21 08:05AM
Jul-21-21 10:30PM
05:27PM
Jul-20-21 08:05AM
Jun-30-21 08:05AM
Jun-29-21 08:05AM
Jun-28-21 01:04PM
Jun-18-21 10:08AM
Jun-04-21 09:01AM
Jun-01-21 08:05AM
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Index -
P/E -
EPS (ttm) -3.57
Insider Own 19.88%
Shs Outstand 11.36M
Perf Week -4.26%
Market Cap 33.38M
Forward P/E -
EPS next Y -4.13
Insider Trans 0.00%
Shs Float 9.16M
Perf Month -28.78%
Income -40.42M
PEG -
EPS next Q -0.80
Inst Own 68.80%
Short Float 4.35%
Perf Quarter 9.77%
Sales 0.00M
P/S -
EPS this Y -1.85%
Inst Trans -4.11%
Short Ratio 1.41
Perf Half Y 134.50%
Book/sh 6.01
P/B 0.49
EPS next Y -13.59%
ROA -42.05%
Short Interest 0.40M
Perf Year -7.30%
Cash/sh 5.74
P/C 0.51
EPS next 5Y -
ROE -47.44%
52W Range 1.04 - 5.24
Perf YTD 55.73%
Dividend Est. -
P/FCF -
EPS past 5Y 39.98%
ROI -55.52%
52W High -44.27%
Beta 1.87
Dividend TTM -
Quick Ratio 11.17
Sales past 5Y 0.00%
Gross Margin -
52W Low 180.77%
ATR (14) 0.32
Dividend Ex-Date -
Current Ratio 11.17
EPS Y/Y TTM 39.08%
Oper. Margin 0.00%
RSI (14) 41.98
Volatility 11.31% 11.10%
Employees 27
Debt/Eq 0.08
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 27.80
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q 73.99%
Payout -
Rel Volume 0.30
Prev Close 2.93
Sales Surprise -
EPS Surprise -5.43%
Sales Q/Q -
Earnings May 02 BMO
Avg Volume 283.09K
Price 2.92
SMA20 -4.65%
SMA50 -20.23%
SMA200 21.10%
Trades
Volume 39,376
Change -0.34%
Index RUT
P/E -
EPS (ttm) -2.06
Insider Own 31.02%
Shs Outstand 24.49M
Perf Week 5.69%
Market Cap 114.38M
Forward P/E -
EPS next Y -1.15
Insider Trans 4.79%
Shs Float 17.01M
Perf Month -12.45%
Income -46.66M
PEG -
EPS next Q -0.49
Inst Own 60.76%
Short Float 5.44%
Perf Quarter -33.52%
Sales 58.45M
P/S 1.96
EPS this Y 17.25%
Inst Trans 17.15%
Short Ratio 6.78
Perf Half Y -20.55%
Book/sh 0.77
P/B 6.02
EPS next Y 32.07%
ROA -63.97%
Short Interest 0.93M
Perf Year -51.00%
Cash/sh 1.90
P/C 2.45
EPS next 5Y -
ROE -281.23%
52W Range 4.23 - 11.26
Perf YTD -29.91%
Dividend Est. -
P/FCF -
EPS past 5Y 5.17%
ROI -76.40%
52W High -58.79%
Beta 0.99
Dividend TTM -
Quick Ratio 3.45
Sales past 5Y 49.61%
Gross Margin 68.62%
52W Low 9.57%
ATR (14) 0.25
Dividend Ex-Date -
Current Ratio 4.23
EPS Y/Y TTM 25.79%
Oper. Margin -75.40%
RSI (14) 40.04
Volatility 3.69% 5.07%
Employees 227
Debt/Eq 2.27
Sales Y/Y TTM 41.13%
Profit Margin -79.83%
Recom 1.00
Target Price 14.60
Option/Short Yes / Yes
LT Debt/Eq 2.24
EPS Q/Q -1.06%
Payout -
Rel Volume 0.28
Prev Close 4.63
Sales Surprise 3.27%
EPS Surprise -18.91%
Sales Q/Q 46.26%
Earnings May 09 AMC
Avg Volume 136.63K
Price 4.64
SMA20 -3.32%
SMA50 -16.02%
SMA200 -31.95%
Trades
Volume 17,322
Change 0.22%
Date
Action
Analyst
Rating Change
Price Target Change
May-31-22 Initiated
Lake Street
Buy
$17
Dec-03-19 Initiated
Piper Jaffray
Overweight
Dec-03-19 Initiated
JMP Securities
Mkt Outperform
Dec-03-19 Initiated
Jefferies
Buy
Dec-03-19 Initiated
Canaccord Genuity
Buy
Apr-25-24 07:00AM
Apr-15-24 07:00AM
Apr-08-24 07:00AM
Mar-22-24 09:46AM
07:07AM
(Thomson Reuters StreetEvents)
08:53PM
Loading…
Mar-21-24 08:53PM
05:32PM
05:30PM
04:05PM
07:00AM
Mar-20-24 07:00AM
07:00AM
Feb-29-24 07:00AM
Feb-23-24 04:05PM
Jan-19-24 04:05PM
04:05PM
Loading…
Dec-15-23 04:05PM
Dec-05-23 07:00AM
Nov-16-23 07:00AM
Nov-12-23 12:20PM
Nov-10-23 04:05PM
Nov-09-23 04:05PM
Oct-26-23 07:00AM
Sep-18-23 04:05PM
Aug-16-23 07:00AM
Aug-11-23 10:03AM
Aug-10-23 09:18AM
(Thomson Reuters StreetEvents)
Aug-09-23 06:05PM
04:03PM
Aug-04-23 04:02PM
Jul-26-23 07:00AM
10:09AM
Loading…
Jul-06-23 10:09AM
Jun-18-23 07:51PM
Jun-15-23 07:00AM
May-25-23 07:00AM
May-21-23 10:30AM
May-19-23 07:00AM
May-12-23 07:44AM
(Thomson Reuters StreetEvents)
May-11-23 05:25PM
04:02PM
May-09-23 07:00AM
May-08-23 04:30PM
May-02-23 07:00AM
Apr-30-23 08:26AM
Apr-28-23 06:47PM
06:47PM
Apr-27-23 07:00AM
Apr-18-23 11:00PM
04:01PM
Apr-03-23 06:14AM
Mar-29-23 07:00AM
Mar-24-23 07:15AM
Mar-23-23 07:00AM
Mar-22-23 06:01AM
(Thomson Reuters StreetEvents) -5.91%
Mar-21-23 05:15PM
04:02PM
Mar-16-23 07:00AM
Feb-28-23 07:00AM
Feb-24-23 04:02PM
Feb-21-23 07:00AM
Feb-14-23 07:00AM
Jan-20-23 04:05PM
Jan-09-23 07:00AM
Dec-23-22 05:46AM
Dec-21-22 07:00AM
Dec-09-22 04:02PM
Nov-21-22 07:00AM
Nov-12-22 07:42AM
Nov-09-22 05:25PM
04:01PM
Nov-03-22 07:00AM
Oct-28-22 04:05PM
Oct-27-22 07:00AM
Oct-26-22 07:00AM
Oct-24-22 10:24AM
Sep-01-22 07:00AM
Aug-23-22 04:01PM
Aug-19-22 10:52AM
(American City Business Journals)
Aug-18-22 04:01PM
Aug-16-22 12:01PM
(American City Business Journals) -11.15%
Aug-15-22 10:20PM
04:01PM
Aug-10-22 10:30PM
05:35PM
04:01PM
Aug-05-22 07:00AM
Aug-04-22 07:00AM
Jul-29-22 04:01PM
Jul-27-22 07:00AM
Jul-20-22 07:00AM
Jul-08-22 06:45AM
Jun-24-22 08:52AM
Jun-23-22 11:02AM
Jun-10-22 06:15AM
Jun-02-22 07:00AM
May-31-22 07:00AM
May-26-22 07:00AM
May-17-22 08:25AM
May-10-22 05:45PM
04:01PM
May-09-22 07:00AM
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Firestone Gregory A. Chief Business Officer Dec 05 '23 Buy 5.65 2,600 14,688 35,511 Dec 07 04:02 PM KOBLISH ANTONY Chief Executive Officer Nov 14 '23 Buy 4.54 11,000 49,976 303,634 Nov 14 08:01 PM Cuca Roberto COO and CFO Nov 14 '23 Buy 4.49 10,000 44,938 62,371 Nov 14 08:02 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite